LBRX Other Current Assets from 2010 to 2026

LBRX Stock   19.36  0.43  2.17%   
LB Pharmaceuticals Other Current Assets yearly trend continues to be fairly stable with very little volatility. Other Current Assets are likely to outpace its year average in 2026. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2010-12-31
Previous Quarter
M
Current Value
1.2 M
Quarterly Volatility
628.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LB Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LB Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 800, Net Interest Income of 2.1 M or Interest Income of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. LBRX financial statements analysis is a perfect complement when working with LB Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with LBRX Stock
Check out the analysis of LB Pharmaceuticals Correlation against competitors.

Latest LB Pharmaceuticals' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of LB Pharmaceuticals Common over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. LB Pharmaceuticals' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LB Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
       Timeline  

LBRX Other Current Assets Regression Statistics

Arithmetic Mean385,467
Geometric Mean160,340
Coefficient Of Variation163.14
Mean Deviation459,537
Median85,000
Standard Deviation628,858
Sample Variance395.5B
Range2.3M
R-Value0.62
Mean Square Error258.9B
R-Squared0.39
Significance0.01
Slope77,384
Total Sum of Squares6.3T

LBRX Other Current Assets History

20261.2 M
2025M
2024880 K
20232.3 M

About LB Pharmaceuticals Financial Statements

LB Pharmaceuticals investors use historical fundamental indicators, such as LB Pharmaceuticals' Other Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LB Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current AssetsM1.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LBRX Stock Analysis

When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.